4SC AG — Capital/Financing Update 2009

Nov 16, 2009

News Details

Ad-hoc | 16 November 2009 14:58

4SC Successfully Completes Capital Increase

4SC AG / Capital Increase

16.11.2009

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Ad hoc announcement in accordance with §15 WpHG [Securities Trading Act]

Capital Increase

4SC Successfully Completes Capital Increase

Planegg-Martinsried, Germany, 16 November, 2009 - 4SC AG (Frankfurt, Prime
Standard: VSC), a drug discovery and development company, today announced
the successful completion of a capital increase, after the Management
Board, with the approval of the Supervisory Board, passed a resolution to
authorise an increase of share capital on 23 October, 2009. The capital
increase from the authorised capital included a collateral rights offering
to existing shareholders at a subscription price of EUR3.00 per share. The
remaining unsubscribed shares were allocated through a private placement in
order to raise in the range of EUR25 to 30 million proceeds. The capital
raising was completed at the top of the range and generated EUR30 million
gross proceeds. The subscribed shares were not fully allocated.

The proceeds will be used to secure the further development of 4SC's
current product pipeline. In particular, the focus will be on the further
development of the Company's clinical compounds against auto-immune and
cancer indications. Proof-of-concept is expected to be achieved within the
next 24 months for the small molecule 4SC-101 in rheumatoid arthritis and
the HDAC inhibitor 4SC-201 in hepatocellular carcinoma (liver cancer). In
addition, preclinical projects will be developed to the stage where they
can be advanced into the clinical pipeline, can provide further value
generation and will ensure risk diversification in the Company's product
portfolio.

Following the completion of the capital increase, a total of 10 million new
shares were placed. As a result of the capital increase, 4SC AG's
subscribed capital increased to EUR38,502,739.00. The free float will be
approximately 19.02% of issued share capital. The approval of the new
shares for trading at the Frankfurt Stock Exchange is expected in December
2009.

The capital increase was accompanied by Conrad Hinrich Donner Bank AG,
Hamburg, Germany.

End of ad hoc notification

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. The company currently has
three clinical programs, with three further clinical trials planned to
commence in 2009. 4SC-101, a small molecule, is in a Phase IIb study in
rheumatoid arthritis as well as in a Phase IIa exploratory study in
inflammatory bowel disease. The company's lead oncology compound, 4SC-201,
a histone deacetylase (HDAC) inhibitor, is in a Phase II trial in
hepatocellular carcinoma and is due to commence a further Phase II trial in
Hodgkin's lymphoma in 2009. Drug candidates are developed until
proof-of-concept in order to generate value creating partnerships with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.

4SC was founded in 1997, has 93 employees, and is listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.

For further information please visit www.4sc.com.

Legal Note

This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

For more information please contact

4SC AG
Yvonne Alexander, IR & PR
Tel.: +49 (0) 89 70 07 63 66

MC Services (Europe)
Stefan Riedel
Tel.: +49 (0) 89 21 02 28 40

The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947

16.11.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---